BioNTech Clinical Data at ELCC 2026 Highlight Potential of Differentiated Late-Stage Portfolio in Lung Cancer

Summary by AI BETAClose X

BioNTech presented promising late-stage lung cancer data at ELCC 2026, highlighting progress with pumitamig, a bispecific immunomodulator, showing encouraging efficacy and safety in extensive-stage small cell lung cancer and advanced non-small cell lung cancer. Additionally, stage 1 results from the PRESERVE-003 trial of gotistobart, a CTLA-4 targeting agent, demonstrated clinically meaningful survival outcomes and antitumor activity in squamous non-small cell lung cancer, with a 54% reduction in the risk of death compared to standard of care. First clinical data for the HER3-targeted ADC, BNT326/YL202, also showed antitumor activity in advanced non-small cell lung cancer, supporting further development and combination studies.

Disclaimer*

UK 100

Latest directors dealings